PharmaEngine

PharmaEngine AAQS

The The AAQS of PharmaEngine (4162.TWO) as of Nov 19, 2026 is 5. In the previous year, The AAQS was 5.00 — a change of 0.00% (lower).

AAQS

5

YoY

0.00%

Last updated:

PharmaEngine has a current AAQS of 5.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock PharmaEngine in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The PharmaEngine AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
5.00 TWD
Jan 1, 2019
5.00 TWD
Jan 1, 2020
5.00 TWD
Jan 1, 2021
5.00 TWD
Jan 1, 2022
5.00 TWD
Jan 1, 2023
5.00 TWD
Jan 1, 2024
5.00 TWD
Jan 1, 2025
5.00 TWD
The PharmaEngine AAQS history
YEARAAQSYoY
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
5—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

The AAQS of PharmaEngine is 5 in 2025.

On Eulerpool you can find the complete historical development of The AAQS PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — PharmaEngine

All Key Metrics — PharmaEngine